Innovative, Evidence-Based GLP-1 Agonist Treatment for Addiction & Recovery
Semaglutide dry mouth profile Semaglutide, marketed as Ozempic and Wegovy, carries a reporting-odds ratio of 1.34 for dry mouth in adverse event databases
GLP-1 Natural Alternatives: Supporting Metabolic Health Beyond Medications GLP-1 Natural Alternatives: Supporting Metabolic Health Beyond Medications | GLP-1 Natural Alternatives: Supporting Metabolic Health Beyond Medications GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed the landscape of type 2 diabetes and obesity care
Understanding the differences between them is essential for making an informed choice, since the medication you select directly affects your cost, results timeline, and side effect experience
A pooled analysis of 3 longer-term RCTs 22,47,48 following 15,820 patients with T2DM up to 3.8 years showed a reduced risk of dementia for semaglutide and liraglutide compared with placebo 39